chemotherapy-induced nausea and vomiting
Oncology · 2009–2023
15decisions
8medicines
4carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| netupitant with palonosetron Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy. | Mar 2023 | Recommended | 1 individuals |
| fosnetupitant/palonosetron Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy and moderately… | Mar 2023 | Recommended with restriction | input received |
| fosnetupitant with palonosetron Prevention of nausea and vomiting associated with cytotoxic chemotherapy in patients receiving moderately and highly emetogenic chemotherapy, including… | Jul 2020 | Recommended with restriction | none received |
| ondansetron Nausea and vomiting associated with radiotherapy or oral chemotherapy being used to treat malignancy. | Mar 2020 | Recommended with restriction | no section in document |
| aprepitant Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic and moderately emetogenic cancer… | Jul 2019 | Recommended with restriction | no section in document |
| aprepitant Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with carboplatin/oxaliplatin regimens from the first chemotherapy… | Mar 2016 | Recommended with restriction | none received |
| fosaprepitant Prevention of nausea and vomiting associated with cytotoxic chemotherapy. Indicated for primary prophylaxis prior to highly emetogenic chemotherapy (HEC) or… | Nov 2016 | Recommended with restriction | none received |
| netupitant with palonosetron Secondary prophylaxis for chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC); and primary prophylaxis for… | Nov 2016 | Recommended with restriction | input received |
| netupitant/palonosetron Prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients treated with highly emetogenic chemotherapy for malignancy, and in breast… | Jul 2015 | Not recommended | input received |
| netupitant/palonosetron Prevention of acute and delayed chemotherapy-induced nausea and vomiting (1-5 days after initiating chemotherapy) in patients scheduled to receive highly… | Mar 2015 | Not recommended | none received |
| aprepitant Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with carboplatin/oxaliplatin-based chemotherapy regimens. | Nov 2015 | Not recommended | none received |
| palonosetron hydrochloride Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy… | Mar 2010 | Recommended with restriction | no section in document |
| aprepitant Management of nausea and vomiting associated with moderately emetogenic cytotoxic chemotherapy in patients who have had a prior episode of chemotherapy-induced… | Mar 2010 | Recommended with restriction | no section in document |
| aprepitant Management of nausea and vomiting associated with moderately emetogenic cytotoxic chemotherapy in patients who have had a prior episode of chemotherapy-induced… | Mar 2010 | Recommended with restriction | no section in document |
| aprepitant Prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic cancer chemotherapy. | Nov 2009 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.